151 related articles for article (PubMed ID: 17662773)
1. Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
Thompson JL; Hamner CE; Potter DD; Lewin M; Sundt TM; Schaff HV
J Thorac Cardiovasc Surg; 2007 Aug; 134(2):359-65. PubMed ID: 17662773
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine.
McKellar SH; Thompson JL; Garcia-Rinaldi RF; Macdonald RJ; Sundt TM; Schaff HV
J Thorac Cardiovasc Surg; 2008 Oct; 136(4):908-14. PubMed ID: 18954629
[TBL] [Abstract][Full Text] [Related]
3. A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses.
McKellar SH; Thompson JL; Schaff HV
J Surg Res; 2007 Jul; 141(1):1-6. PubMed ID: 17512549
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
McKellar SH; Abel S; Camp CL; Suri RM; Ereth MH; Schaff HV
J Thorac Cardiovasc Surg; 2011 Jun; 141(6):1410-6. PubMed ID: 21429525
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model.
Greiten LE; McKellar SH; Rysavy J; Schaff HV
Eur J Cardiothorac Surg; 2014 May; 45(5):914-9. PubMed ID: 24306948
[TBL] [Abstract][Full Text] [Related]
6. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Eriksson BI; Bergqvist D; Kälebo P; Dahl OE; Lindbratt S; Bylock A; Frison L; Eriksson UG; Welin L; Gustafsson D;
Lancet; 2002 Nov; 360(9344):1441-7. PubMed ID: 12433510
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
Gruber A; Carlsson S; Kotzé HF; Marzec U; Sarich TC; Hanson SR
Thromb Res; 2007; 119(1):121-7. PubMed ID: 16448687
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran in orthopaedic surgery.
Eriksson B
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():10-7. PubMed ID: 15812199
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Sarich TC; Eriksson UG; Mattsson C; Wolzt M; Frison L; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):300-5. PubMed ID: 11858491
[TBL] [Abstract][Full Text] [Related]
10. Safety of outpatient dalteparin therapy in veterans with mechanical heart valves.
O'Neill JL; Flanagan PS; Zaleon CR; Copeland LA
Pharmacotherapy; 2005 Nov; 25(11):1560-5. PubMed ID: 16232019
[TBL] [Abstract][Full Text] [Related]
11. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Boström SL; Hansson GF; Kjaer M; Sarich TC
Blood Coagul Fibrinolysis; 2003 Jul; 14(5):457-62. PubMed ID: 12851531
[TBL] [Abstract][Full Text] [Related]
12. [The oral direct thrombin inhibitor Ximelagatran Prophylaxis of venous thromboembolism in hip and knee replacement].
Mouret P
Hamostaseologie; 2002 Aug; 22(3):21-4. PubMed ID: 12215757
[TBL] [Abstract][Full Text] [Related]
13. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
Wolzt M; Sarich TS; Eriksson UG
Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of the oral direct thrombin inhibitor ximelagatran.
Mattsson C; Sarich TC; Carlsson SC
Semin Vasc Med; 2005 Aug; 5(3):235-44. PubMed ID: 16123910
[TBL] [Abstract][Full Text] [Related]
15. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation.
Giraud S; Thuillier R; Belliard A; Hebrard W; Nadeau C; Milin S; Goujon JM; Manguy E; Mauco G; Hauet T; Macchi L
Transplantation; 2009 Jun; 87(11):1636-44. PubMed ID: 19502954
[TBL] [Abstract][Full Text] [Related]
16. Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Attman PO; Ottosson P; Samuelsson O; Eriksson UG; Eriksson-Lepkowska M; Fager G
Nephrol Dial Transplant; 2005 Sep; 20(9):1889-97. PubMed ID: 15928099
[TBL] [Abstract][Full Text] [Related]
17. Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Scherstén F; Wahlund G; Björnheden T; Carlsson S; Mattsson C; Grip L
Blood Coagul Fibrinolysis; 2003 Apr; 14(3):235-41. PubMed ID: 12695745
[TBL] [Abstract][Full Text] [Related]
18. The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
Hellgren M; Johansson S; Eriksson UG; Wåhlander K
BJOG; 2005 May; 112(5):579-83. PubMed ID: 15842280
[TBL] [Abstract][Full Text] [Related]
19. Managing mechanical valves with reduced anticoagulation.
Slaughter MS; Jweied E
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1073-85. PubMed ID: 18035923
[TBL] [Abstract][Full Text] [Related]
20. Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Carlsson S; Elg M; Mattsson C
Thromb Res; 2002 Aug; 107(3-4):163-8. PubMed ID: 12431484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
